Reversing Age-Related Hair Loss in Women
Hair loss isn’t exclusively a male problem – approximately 50% of all women over the age of 50 experience a similar condition, referred to as female androgenetic alopecia. Symptoms in women are generally less severe than those experienced by men, appearing as an overall thinning of hairs across the top of the head, and the gradual loss of hairs down the center part-line of the scalp. The reason women experience milder symptoms is due to hormonal differences – women produce significantly lower amounts of testosterone than men (about 95% less on average). Women also produce lower levels – about 60 percent less than men – of the enzyme 5α-reductase that converts testosterone into DHT.
Additionally, women produce higher levels of another enzyme, aromatase (estrogen synthase), that converts testosterone into the female hormone, estradiol. While males also produce small amounts of aromatase, research has shown that aromatase levels in the frontal and rear scalp follicles in women are four to six times higher than in men, which is why women rarely lose hair in these areas.
Human Trials - Alopecia Totalis
Following the positive outcome of the male pattern baldness trials, the researchers began to test the new formula on several women diagnosed with Alopecia totalis, a condition that causes lymphocytes to attack hair follicles during the growth phase of the hair cycle. In extreme cases, Alopecia totalis can result in the total loss of hair on the head, face, eyebrows and eyelashes within six months. Full recovery is rare, and even with effective treatment, new hair growth in patients with alopecia totalis is often incomplete.
• CASE 1: Ms. Y., 26-years-old, was diagnosed with Alopecia totalis in July, 2006. Early signs of hair loss were attributed to stress from work and school, but within two months all of the hair on her head, eyebrows included, had dropped out. Conventional treatment failed to address the problem, and when Ms. Y. entered the trial all that remained were a few black strands in the occipital region (Fig. 1). After taking PriaPlex for six months, new hair began to appear (Fig. 2). After two years of treatment, Ms. Y. fully regrew her hair. (Fig. 3) Two years after completing treatment, Ms. Y. reports that her hair is still full and strong, with good volume and no further loss.CASE 2: Ms. L. had previously tried every other available treatment to reverse her hair loss, but all failed. She had been completely bald for eight years by the time she enrolled in the trial. After taking the formula for six months, there was no improvement in her condition and Ms. L. decided to discontinue treatment (see note).
CASE 3: Ms. H., 28-years-old, experienced serious, unexplained hair loss in the summer of 2007, and within two months had lost all of her hair, including eyebrows (Fig. 4). Ms. H. began to experience new hair growth within two months of taking PriaPlex (Fig. 5). Significantly, Ms. H. reported that her previously white hair was growing back in her natural color, black (Fig. 6). The researchers expected that newly grown hair would not regain its original color for at least 2 or 3 full hair cycles, so her case was especially interesting. Ms. H. reached a near-full recovery in six months. Unfortunately, Ms. H. stopped taking PriaPlex after her initial treatment and experienced a relapse after six months.NOTE: Each of the cases of Alopecia Totalis discussed above resulted in completely different outcomes: the first was successful, the second ineffective, and the third a relapse. Note that in the third case, researchers had previously predicted that newly grown hair would not regain its original color for at least two or three full hair cycles, so her case was especially interesting.
SUMMARY: From these cases the scientists concluded that the longer one waits before beginning treatment with PriaPlex, the greater the chances for permanent and unrecoverable damage to hair follicles. The scientists also concluded that early treatment at the first signs of hair loss improves the probability of total recovery. Additionally, treatments have to be continued until the underlying condition is eliminated to prevent a future recurrence of hair loss.
Next: Halting Hair Loss and Restoring Hair Growth Cycles
Reversing Age-Related Hair Loss in Men
Male-pattern hair loss (Fig. 1), also known as androgenetic alopecia, is the most common form of balding, affecting roughly 40 million men in the US. Approximately 25 percent of men with male-pattern hair loss will begin to lose their hair by age 30, and up to 66 percent will begin balding by age 60. Male pattern hair loss is closely linked to androgens – sex steroid hormones synthesized from cholesterol in the testes, ovaries and adrenal glands. The primary androgens – testosterone, pregnenolone, androstenedione and DHEA (dehydroepiandrosterone) – normally regulate male and female sexual development and behavior by binding to receptors on target cells throughout the body.
Fig. 1. Progressive loss of hair as classified on the
Hamilton–Norwood chart, ranging from stages I through VII.
Another androgen, dihydrotestosterone (DHT), has been identified by researchers as a primary cause of male pattern baldness. DHT is synthesized from testosterone by the enzyme 5-alpha-reductase. When DHT binds to receptors in the hair follicle, it causes the hair roots to shrink, or "miniaturize.” DHT has also been shown to shorten the amount of time hair spends in the growing (anagen) phase from as long as five years to as little as two months.
In 1998, researchers discovered that men genetically prone to male pattern baldness have significantly higher numbers of androgen receptors in the hair follicles located across the forehead and scalp – exactly those areas where hair loss first appears in androgenetic alopecia. Additional research has shown that these androgen-sensitive follicles also have significantly higher levels of 5-alpha-reductase (1.5 to 3 times higher) and DHT than hair follicles from other areas of the scalp.
Over time, DHT’s miniaturizing effect can shrink large adult hairs, resulting in finer, vellus hairs only 10% as wide as normal and barely an inch long. This leads to the “peach fuzz” common to early stage balding. At this stage if the effects of DHT aren’t reversed or halted in time, the hair follicles will shrink down until they eventually vanish, resulting in complete baldness in the affected area.
Human Trials – Alopecia Areata
The earliest trials of PriaPlex involved a group of patients diagnosed with Alopecia areata, or “spot areata,” a condition that causes clumps of hair to fall out with a gentle pull, leaving patients with one or more bare spots on the scalp. Alopecia areata occurs in young people at a rate of approximately 17 per 100,000 per year, and while the condition isn’t harmful, the psychological impact is problematic for young patients. Fortunately, the condition is generally temporary, and 80% of the patients eventually recover.
The most common treatment for Alopecia areata involves monthly injections of corticosteroids, and twice-a-day external application of 5% minoxidil. Treatment generally requires 8-12 weeks before hair begins to regrow.
One of the early test subjects, Mr. W., was a 50-year-old sales manager who had lost a large amount of hair in the occipital region. He came to the center after being treated with steroids for one month. The steroids had not alleviated his alopecia areata, and the area of hair loss was continuing to spread. Shortly after starting the trial Mr. W. reported significant improvement in his condition.
Male Pattern Baldness
Pleased with the results of the Alopecia trial the researchers began to evaluate the formula for male pattern baldness. Early results revealed that most men with stage 3 or 4 hair loss reacted within six months, with fine hairs appearing on the top of the scalp that grew thicker and longer over time. Men with stage 4 to 5 hair loss were more likely to experience significant regrowth; however, improvements in stage 7 male-pattern baldness were only noticeable close up, with thinner hairs becoming thicker and longer, but with little change on the forehead.
The images below (Figures 7 through 9) document the results of three separate cases of male pattern baldness after treatment with PriaPlex.
Next: Halting Hair Loss and Restoring Hair Growth Cycles
It turns out stress does turn hair gray, and now researchers know how.
Stress triggers the body’s fight-or-flight response, which in turn causes pigment-producing cells that give hair its color to go into a frenzy and dwindle in number, researchers report online January 22 in Nature. As these pigment cells disappear, so does the color.
Gray hair has been linked to stress for centuries — think of U.S. presidents before and after holding office. But scientists didn’t understand how stress makes hair go gray.
“It was satisfying to question a popular assumption … [and] to identify the mechanisms that now open up new areas of work,” says Ya-Chieh Hsu, a stem cell biologist at Harvard University.
Hsu and her colleagues stressed mice by injecting them with a compound closely related to capsaicin, the active ingredient in chili peppers. Within five days, the rodents’ hair turned white. After eliminating the immune system and the stress hormone cortisol as causes of the color change, the team discovered that part of the animals’ nervous system was depleting pigment cells from hair.
In hair follicles, cells called melanocyte stem cells color hair by converting into pigment-producing cells. The body can’t replenish the stem cells, so as these cells are used up, color vanishes. Sensory stress triggered a mouse’s sympathetic nervous system — which controls the body’s fight-or-flight response to stress — to release the neurotransmitter norepinephrine, the team found. That compound over activates the reservoir of stem cells, setting off a flurry of conversion into pigment-producing cells. That, in turn, rapidly uses up the stem cells supply.
It’s unclear why stress makes hair gray — an event also typically tied to getting older. But the work raises questions about whether stress-related graying is the same as aging, and lays the foundation for exploring other ways that stress affects the body.
Client Comments on PriaPlex and Gray Hair
Hair colour 11/19/2019
I use the product to replicate my natural colour and it seems to be working I can see dark roots of hair growing bringing my hair colour to it’s natural colour with much less grey. Cheers Clancy Cosgrove from Edmonton Alberta Canada.
Hi there, I’m not certain and I believe it is barley a month but it seems my hair could be a bit thicker… stronger ? It could be just me thinking that. Not sure if the grey is going away though. Hopefully, as time goes on, I will see the benefits of the product
Hair’s the scoop! 08/26/2015
I started taking PriaPlex about 1 year ago. I was noticing that my hair was thinning which I believe has to do with taking Thyroid medication which I have to take. After a few months my hairdresser noticed new growth & although I have very little grey hair for my age, the new growth was coming in my normal color brown. Very pleased . While my hair will never be as thick as it was before my Thyroid issues , I am not losing hair as I once was. Expect continued success.
PriaPlex Reviw 06/22/2016
I have not taken PriaPlex long enough for a fair evaluation. The supplement literature indicates at least six months’ use before seeing results of hair restoration. However, I will say that all the ingredients are sound and could have other benefits, as well. Also, having used PriaPlex for four months I think I see a decrease in hair loss and graying. I am fairly certain of this. At this point it is too soon for me to give an unequivocal thumbs up, but I am satisfied enough to continue using PriaPlex. I would tell someone concerned about hair loss to read the literature and if they need a little encouragement I would say it’s worth a try.
Hair maintenance 10/01/2015
Hair is definitely not as gray as it use to be and stopped falling out, and my hairline is filling in. Very happy with product.
Hair re-growth and gray eyebrows turning brown! 07/21/2014
I started losing my hair when I was 19. It started receding in typical mail pattern baldness. I am now 66 and I have a horseshoe around the sides and the back of my head, and I’m about 70% gray. My eyebrows have been totally white for the last few years. I have a few strands that grow longer on the sides that I put over the top - I know its futile, but it’s better than nothing. After 6-8 weeks of taking PriaPlex I noticed the color of a few strands of hair changing, first in my eyebrows and later on my temples. A few of my eyebrow hairs had grown in brown. That’s what made me look at my hair more closely, and I noticed that some fuzz had started growing on the crown of my head. At first I thought it was my imagination, but on closer inspection, I confirmed that hair actually was growing. My mother had always told me that I could stimulate hair growth by brushing my scalp with a soft brush, which I have done for years with no result. I believe that PriaPlex has provided my body the nutrients it needed to re-grow hair. After 3 months on PriaPlex I found there were fewer hairs in my brush. As opposed to subjective results, this is a change I can really see, so I know its working. I am very happy with my results and plan to continue taking PriaPlex in the hopes of more hair regrowth and color change. -James F.
Researchers recently completed a six-month, randomized, double-blind placebo controlled study designed to evaluate the efficacy of PriaPlex® for male pattern baldness (Androgenetic Alopecia, or AA). Researchers enrolled 40 patients (31 male, 9 female) diagnosed with male pattern baldness. At the end of six months, 32 patients had completed the full trial, and 8 had dropped out due to non-compliance issues (5 in the placebo group and 3 in the treatment group).
The study found that 9 of the 17 treatment subjects taking PriaPlex (52.9%) experienced significant hair growth, as measured by dermatoscopy and clinical photographs independently scored by dermatologists blind to the treatment conditions (Fig. 1). By comparison, only 2 of the 15 subjects (13%) receiving the placebo showed any signs of hair growth.
The primary goal of this short, six-month study was to determine the efficacy of the formula in the intention-to-treat population — i.e., men and women with androgenetic alopecia. The significance of these results, after only six-months of treatment, become especially apparent when compared to similar measurements after treatment with Finasteride for 1 year (44%), 2 years (61%) and 5 years (48%) of use (Fig. 2).
One of the most interesting outcomes of the study was that each of the subjects receiving PriaPlex reported that their previous abnormal hair loss halted during the trial. In other words, PriaPlex completely stopped age-related hair loss in 100% of the cases.
By age 35, two-thirds of American men will have some degree of appreciable hair loss and by age 50 approximately 85% of men have significantly thinning hair. About 25% of men who suffer from male pattern baldness begin the painful process before they reach 21. Contrary to societal belief, most men who suffer from male pattern baldness are extremely unhappy with their situation and would do anything to change it. And hair loss isn’t an exclusively male issue — approximately 50% of all women over the age of 50 experience a similar condition referred to as female androgenetic alopecia.
In this short six-month trial, 100% of both male and female subjects taking PriaPlex for androgenetic alopecia experienced a total cessation of abnormal hair loss, and 53% experienced significant new hair growth. In addition to stopping the progression of age-related hair loss, PriaPlex was shown to support restoration of healthier, thicker hair in existing follicles.
Additional studies are underway to determine a fuller clinical picture of longer periods of continuous use of PriaPlex.
Patients between 20 to 45 years old of both sexes with androgenetic alopecia were enrolled in the clinical trial. Exclusion criteria included hormone imbalances, metabolic diseases, cancers, unknown etiology of alopecia, infection, irritation or pain in the scalp. The pilot study, lasting 6 months, was a randomized, double-blind, placebo-controlled study involving 40 patients. 20 patients in the treatment group received 6 caplets of PriaPlex® daily (3 grams), and 20 patients received placebo. Male patients were diagnosed with alopecia based on the Norwood-Hamilton scale, and female patients were diagnosed with alopecia based on the Ludwig scale. Dermatoscopy and clinical macrophotographs were recorded monthly and independently scored by three dermatologists blind to treatment condition. Each patient was monitored with full lab clinical tests to measure TSH, DHEAs, testosterone, estrogen, kidney and liver function tests, and complete blood count. Clinical endpoints include Norwood-Hamilton and Ludwig scale, Fatigue Symptom Inventory, self-reporting hair loss, and color of hair. Adverse events were also monitored (none reported). Chi-square test was 0.01